{"id":"cd22","name":"CD22","symbol":"CD22","route":"/targets/cd22/","asOf":"2026-09-07","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1643","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012124","uniprot":"https://www.uniprot.org/uniprotkb/P20273/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P20273","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3218","open-targets":"https://platform.opentargets.org/target/ENSG00000012124","civic":"https://civicdb.org/genes/933/summary","oncokb":"https://www.oncokb.org/gene/CD22","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD22","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD22","depmap":"https://depmap.org/portal/gene/CD22?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000012124-CD22","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/933","omim":"https://www.omim.org/entry/107266"}],"products":[{"id":"azd4512","name":"AZD4512","status":"phase-2","modality":"ADC","route":"/drugs/azd4512/"},{"id":"inotuzumab-ozogamicin","name":"Inotuzumab ozogamicin","status":"approved","modality":"ADC","route":"/drugs/inotuzumab-ozogamicin/"},{"id":"moxetumomab-pasudotox","name":"Moxetumomab pasudotox","status":"withdrawn","modality":"Anti-CD22 immunotoxin (Pseudomonas exotoxin A fragment)","route":"/drugs/moxetumomab-pasudotox/"},{"id":"ucart22","name":"UCART22","status":"phase-2","modality":"allogeneic CAR T-cell therapy","route":"/drugs/ucart22/"}],"trials":[{"id":"nct01829711","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","nct":"NCT01829711","phase":"3","status":"completed"},{"id":"ino-vate","name":"INO-VATE ALL","nct":"NCT01564784","phase":"3","status":"positive"},{"id":"nct03150693","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","nct":"NCT03150693","phase":"3","status":"recruiting"},{"id":"nct05748171","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","nct":"NCT05748171","phase":"2","status":"recruiting"},{"id":"nct02338050","name":"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","nct":"NCT02338050","phase":"2"},{"id":"nct07123454","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","nct":"NCT07123454","phase":"1/2","status":"recruiting"},{"id":"nct04150497","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","nct":"NCT04150497","phase":"1/2","status":"recruiting"},{"id":"nct07109219","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","nct":"NCT07109219","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["astrazeneca","cellectis","pfizer"],"keyPapers":["paper-ino-vate-inotuzumab-all-nejm-2016"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}